S. Dearden

发表

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Gillian Ellison, R. McCormack, G. Ellison, 2012, Journal of Clinical Pathology.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Ying Cheng, E. Cho, S. Ramalingam, 2019, Clinical Cancer Research.

Molecular analysis of HLA-DQB1 alleles in childhood common acute lymphoblastic leukaemia.

G. M. Taylor, M. Robinson, J. Birch, 1996, British Journal of Cancer.

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

J Carl Barrett, Tracey Hammett, J. Barrett, 2015, Lung cancer.

Increased frequency of Fanconi anemia group C genetic variants in children with sporadic acute myeloid leukemia.

J. Birch, A. Awan, S. Dearden, 1998, Blood.

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib

P. Jänne, F. Shepherd, J. Yang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular Diagnostics

G. Ellison, C. Dive, R. Tuan, 2015, The Journal of the American Academy of Orthopaedic Surgeons.

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

M. Ranson, G. Ellison, C. Dive, 2009, British Journal of Cancer.

Preliminary evidence of an association between HLA-DPB1*0201 and childhood common acute lymphoblastic leukaemia supports an infectious aetiology.

G. M. Taylor, M. Robinson, J. Birch, 1995, Leukemia.

Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.

J. Barrett, D. Hodgson, J. Lanchbury, 2021, Gynecologic oncology.

Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours

C. Harbron, D. Hodgson, A. Lau, 2013, Virchows Archiv.

Molecular genetic analysis of a family with a history of Hodgkin's disease and dyschondrosteosis.

G. M. Taylor, D. Evans, P. Woll, 1995, Leukemia.

Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.

J. Barrett, D. Hodgson, E. Harrington, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

Yi-long Wu, S. Dearden, Y. Wu, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.

David M. Wilson, P. Hoff, S. Dearden, 2013, European journal of cancer.

Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy

Thomas Walker, R. Shaw, I. Hampson, 2018, Scientific Reports.

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

N. Agarwal, G. Kramer, M. Carducci, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

N. Agarwal, J. Barrett, C. Corcoran, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Edward S. Kim, X. Wang, I. Wistuba, 2013, Clinical Cancer Research.

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

R. McCormack, S. Dearden, Simon Dearden, 2015, American journal of cancer research.

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC

R. McCormack, T. Ciuleanu, J. Douillard, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

S. Dearden, Jill Walker, James L Sherwood, 2015, Journal of experimental & clinical cancer research : CR.

EGFR T790M mutation testing within the osimertinib AURA Phase I study.

P. Jänne, M. Ranson, H. Brown, 2017, Lung cancer.

Infantile osteopetrosis; bone marrow transplantation from a cousin donor.

G. M. Taylor, S. Dearden, R. Stevens, 1995, Archives of disease in childhood.

Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201.

G. M. Taylor, M. Greaves, F. Alexander, 2002, Human molecular genetics.

Evidence that an HLA-DQA1-DQB1 haplotype influences susceptibility to childhood common acute lymphoblastic leukaemia in boys provides further support for an infection-related aetiology.

G. M. Taylor, J. Birch, S. Dearden, 1998, British Journal of Cancer.

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

S. Dearden, Jill Walker, James L Sherwood, 2015, Journal of experimental & clinical cancer research : CR.